Abate D, Tedla Y, Meressa D, Ameni G (2014). Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. International Journal of Tuberculosis and Lung Disease 18(8):946-951.
Crossref

Abdella K, Abdissa K, Kebede W, Abebe G (2015). Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia. BMC Public Health 15:599.
Crossref

Barroso EC, Salani Mota RM, Santos RO, Oliveira Sousa AL, Barroso JB, Rodrigues JL (2003). Risk factors for acquired multidrug-resistant tuberculosis. Journal de Pneumologia 29(2):89-97.
Crossref

Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD (2010). Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medecine 363:1005-1015.
Crossref

Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins M (2011). Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet, 377(9776):1495-1505.
Crossref

Chen S, Huai P, Wang X, Zhong J, Wang X, Wang K, Wang L, Jiang S, Li J, Peng Y, Ma W (2013). Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case-control study. International Journal of Infectious Disease 17:1116-1120.
Crossref

Hamusse SD, Hussen MS, Meaza Demissie M, Bernt L (2016). Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia. BMC Public Health 16:593.
Crossref

Lomtadze N, Aspindzelashvili R, Janjgava M, Mirtskhulava V, Wright A, Blumberg HM, Salakaia A (2009). Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. International Journal of Tuberculosis and Lung Disease 13(1):68-73.

Mekonnen F, Tessema B, Moges F, Gelaw A, Eshetie S, Kumera G (2015). Multidrug resistant tuberculosis: prevalence and risk factors in districts of Metema and West Armachiho, Northwest Ethiopia. BMC Infectious Disease 15:461.
Crossref

Metcalfe JZ, Makumbirofa S, Makamure B, Sandy C, Bara W, Mason P, Hopewell PC (2016). Xpert(®) MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe. International Journal of Tuberculosis and Lung Disease 20(7):882-889.
Crossref

Minime-Lingoupou F, Manirakiza A, Yango F, Zandanga G, Le Faou A, Rigouts L (2015). Relatively low primary resistance to anti-tuberculosis drugs in Bangui and Bimbo, Central African Republic. International Journal of Tuberculosis and Lung Disease 15(5):657-661.
Crossref

Minime-Lingoupou F, Pierre-Audigier C, Kassa-Kélémbho E, Barilone N, Zandanga G, Rauzier J, Cadet-Daniel V, Le Faou A, Gicquel B (2010). Rapid identification of multidrug-resistant tuberculosis isolates in treatment failure or relapse patients in Bangui, Central African Republic. International Journal of Tuberculosis and Lung Disease 14(6):782-785.

Misombo-Kalabela A, Nguefac-Tsague G, Kalla GCM, Afane Ze E, Diangs K, Panda T, Kebela I , Fueza SB, Magazani N , Mbopi-Kéou FX (2016). Risk factors for multidrug-resistant tuberculosis in the city of Kinshasa in the Democratic Republic of Congo. Pan African Medical Journal 23:157.
Crossref

Mulisa G, Workneh T, Hordofa N, Suaudi M, Abebe G, Jarso G (2015). Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia Region of Ethiopia. International Journal of Infectious Disease 39:57-61.
Crossref

Olusoji D, Eltayeb O (2016). Prevalence and risk factors associated with drug resistant TB in South West, Nigeria. Asian Pacific Journal of Tropical Medecine 4(2):148-51.
Crossref

Pimkina E, Zablockis R, Nikolayevskyy V, Danila E, Davidavicience E (2015). The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania. Respiratory Medecine 109(11):1484-1489.
Crossref

Sabeel SM, Salih MA, Ali M, El-Zaki SE, Abuzeid N, Elgadi ZA, Altayb HN, Elegail AM, Ibrahim NY, Elamin BK (2017). Phenotypic and Genotypic Analysis of Multidrug-Resistant Mycobacterium tuberculosis Isolates from Sudanese Patients. Tuberculosis Research and Treatment 2017:8340746.
Crossref

Sangaré L, Diandé S, Badoum G, Dingtoumda B, Traoré AS (2010). Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso. International Journal of Tuberculosis and Lung Disease 14(11):1424-1429.

Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N (2014). Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database of Systematic Review 2014(1):CD009593.
Crossref

Suárez-García I, Rodriguez-Blanco A, Vidal-Pérez JL, García-Viejo MA, Jaras-Hernández MJ, López O, Noguerado-Asensio A (2009). Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. European Journal of Clinical Microbiology and Infectious Disease 28(4):325-330.
Crossref

World Health Organization (WHO) (2014). Xpert MTB/RIF Implementation. Manual: Technical and Operational 'How-To'; Practical Considerations. WHO Guidelines Approved by the Guidelines Review Committee. PMID: 25473699 NBK254323.

World Health Organization (WHO) (2019). Global Tuberculosis Report 2019.

View